Download presentation
Presentation is loading. Please wait.
Published byColeen George Modified over 6 years ago
1
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer, MD, Edward M. Kerwin, MD, Mark C. Liu, MD, Nan Zhang, PhD, Yun Chon, PhD, Alison L. Budelsky, PhD, Joseph Lin, MD, Shao-Lee Lin, MD, PhD Journal of Allergy and Clinical Immunology Volume 131, Issue 2, Pages (February 2013) DOI: /j.jaci Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Change from baseline in total ACQ score for patients receiving placebo, 5 mg of AMG 853 BID, 25 mg of AMG 853 BID, 100 mg of AMG 853 BID, and 200 mg of AMG 853 QD. BL, Baseline. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Fig 2 Change from baseline in prebronchodilator percent predicted FEV1 for patients receiving placebo, 5 mg of AMG 853 BID, 25 mg of AMG 853 BID, 100 mg of AMG 853 BID, and 200 mg of AMG 853 QD. BL, Baseline. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.